Human mutations in MLL1 (KMT2A) and MLL2 (KMT2B) have been associated with cancer and syndromic neurological and psychiatric disorders, such as dystonia, intellectual disability and autism with variable age onsets (Jones et al., 2012; Meyers et al., 2017). The gene discussed is KMT2B; the disease is cancer.